Rezolute, Inc. (RZLT)
| Market Cap | 438.47M -48.3% |
| Revenue (ttm) | n/a |
| Net Income | -77.59M |
| EPS | -0.75 |
| Shares Out | 104.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,587,556 |
| Open | 3.850 |
| Previous Close | 3.900 |
| Day's Range | 3.760 - 4.195 |
| 52-Week Range | 1.070 - 11.457 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 8.78 (+110.05%) |
| Earnings Date | Sep 24, 2026 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for RZLT stock is "Buy." The 12-month stock price target is $8.78, which is an increase of 110.05% from the latest price.
News
Rezolute price target raised to $10 from $6 at Jones
Jones raised the firm’s price target on Rezolute (RZLT) to $10 from $6 and keeps a Buy rating on the shares after the company reported Q4 results. In the open-label…
Rezolute price target raised to $10 from $5 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rezolute (RZLT) to $10 from $5 and keeps a Buy rating on the shares. The company continues to target…
Rezolute reports Q4 EPS (20c), consensus (14c)
Cash, cash equivalents and investments in marketable securities were $107.8M as of June 30, compared with $167.9M as of June 30, 2025. upLIFT, a Phase 3, single-arm, open label study…
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypogl...
Rezolute Earnings release: Q4 2026
Rezolute released its Q4 2026 earnings on September 24, 2026, summarizing the period's financial results.
Rezolute Annual report: Q4 2026
Rezolute has published its Q4 2026 annual report on September 24, 2026.
Rezolute provides update on FDA review of sunRIZE study
Rezolute (RZLT) provided an update on the status of the ongoing FDA review of data from the company’s Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due…
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a ...
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemi...
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia...
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on June 26, 2026.
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenita...
Rezolute price target raised to $11, named a Best Idea at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Rezolute (RZLT) to $11 from $6 and keeps a Buy rating on the shares, which the analyst is also naming…
Rezolute Transcript: Jefferies Global Healthcare Conference 2026
Interim tumor HI data show strong efficacy, with top-line results and regulatory updates expected in the second half of the year. Both tumor and congenital HI programs are on track for potential BLA filings in 2025, with robust pricing and a 3,000-patient initial market opportunity.
Rezolute Slides: FY 2026
Rezolute has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia...
Rezolute price target raised to $14 from $10 at Maxim
Maxim raised the firm’s price target on Rezolute (RZLT) to $14 from $10 and keeps a Buy rating on the shares. The firm cites the company having announced interim data…
Rezolute price target raised to $6 from $5 at Wedbush
Wedbush analyst Yun Zhong raised the firm’s price target on Rezolute (RZLT) to $6 from $5 and keeps an Outperform rating on the shares. The interim data that Rezolute reported…
Rezolute upgraded to Outperform from Market Perform at Citizens
Citizens upgraded Rezolute (RZLT) to Outperform from Market Perform with an $11 price target The interim Phase 3 results for ersodetug in tumor hyperinsulinism increase confidence that the approval pa...
Rezolute price target raised to $6 from $5 at BTIG
BTIG raised the firm’s price target on Rezolute (RZLT) to $6 from $5 and keeps a Buy rating on the shares after the company provided an interim update on its…
Rezolute price target raised to $14 from $10 at Maxim
Maxim raised the firm’s price target on Rezolute (RZLT) to $14 from $10 and keeps a Buy rating on the shares after the company provided an interim update on its…
Rezolute provides interim update on ersodetug study
Rezolute (RZLT) provided an interim update on its ongoing open-label Phase 3 study of ersodetug in tumor HI. With eight participants enrolled in upLIFT to date, comprising both insulinoma and…
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second ...
Rezolute price target raised to $10 from $4 at Maxim
Maxim raised the firm’s price target on Rezolute (RZLT) to $10 from $4 and keeps a Buy rating on the shares after its Q3 results. The company’s Ersodetug, which had…